NVS240920C95000
- 23.00
- 0.000.00%
Novartis AG Newsroom
Novartis Kisqali Gains Early Breast Cancer Indication
FDA Approves Novartis Kisqali To Reduce Risk Of Recurrence In People With HR+/HER2- Early Breast Cancer
Major breakthrough in cancer treatment? Pharmaceutical companies invest billions of dollars, competing to bet on targeted radiation therapy.
Radioactive drugs have the potential to become a significant breakthrough in cancer treatment. In the past year, global pharmaceutical giants such as bristol-myers squibb, astrazeneca, and eli lilly and co have invested approximately 10 billion US dollars to actively enter the field of radioactive drugs through acquisitions and collaborations, aiming to replicate the success of Novartis in the drugs Lutathera and Pluvicto. Currently, these radioactive drugs are mainly used to treat certain types of neuroendocrine tumors and prostate cancer, with the potential to expand to the treatment of more types of cancer in the future.
Liquidia Says United Therapeutics' Interference Found by US Court to Have Caused Losses of Over $137 Million
In An Updated Analysis From Phase 3 NATALEE Trial Of Novartis' Kisqali (Ribociclib) Added To Endocrine Therapy Shows Deepening Benefit Beyond Three-year Treatment Period, Reducing Risk Of Recurrence By 28.5%, Compared To ET Alone, For Stage II And III...
J&J Leads H1 Healthcare Deals as Big Pharma Dealmaking Returns: Report
Buy Rating Affirmed: Novartis AG's Strong Growth Outlook and Underestimated Pipeline Potential
Express News | Novartis' innovative drug Tuo Ruida has issued the first batch of prescriptions nationwide.
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Novartis AG (NOVN) Receives a Buy From UBS
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
Novartis Lower as BofA Downgrades on Risks to Valuation
B of A Securities Downgrades Novartis to Neutral, Lowers Price Target to $130
BofA Securities Downgrades Novartis AG(NVS.US) to Hold Rating, Raises Target Price to $130
BofA Securities analyst Graham Parry downgrades $Novartis AG(NVS.US)$ to a hold rating, and adjusts the target price from $118 to $130.According to TipRanks data, the analyst has a success rate of 57.
Express News | The United Kingdom's economy did not show any growth in July.
Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk
Novartis to License VYGR's Capsid for Gene Therapy in Neurology
BMO Capital Maintains Novartis AG(NVS.US) With Hold Rating, Maintains Target Price $118
BMO Capital analyst Etzer Darout maintains $Novartis AG(NVS.US)$ with a hold rating, and maintains the target price at $118.According to TipRanks data, the analyst has a success rate of 57.6% and a